{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-23-000063","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.532947+00:00","generated_at":"2026-06-11T22:20:12.383407+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avanos Q2 sales $169.4M, adjusted EPS $0.24; FY2023 adjusted EPS guidance $1.05-$1.15","bullets":["Q2 net sales $169.4M (-0.9% YoY); net loss $4.3M vs net income $4.8M a year ago.","Adjusted diluted EPS $0.24 vs $0.26; adjusted EBITDA flat at $22.9M.","Closed Diros Technologies acquisition (RFA) in July; recorded $72.3M impairment on Respiratory Health divestiture.","UK NICE recommends RFA for osteoarthritic knee pain, potentially improving Pain Management reimbursement.","FY2023 outlook: adjusted EPS $1.05-$1.15, adjusted gross margin >59%, H2 organic growth low single-digit."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-23-000063","json":"https://secwatch.observer/filing/0001606498-23-000063.json","markdown":"https://secwatch.observer/filing/0001606498-23-000063.md","text":"https://secwatch.observer/filing/0001606498-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000063/0001606498-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000063/avns-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:20:12.383407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5fa28352ee474739262556208143eebec4ca1b5","claim":"AVANOS MEDICAL, INC. reported financial results for the three and six months ended June 30, 2023.","evidence_excerpt":"Avanos Medical, Inc. (the “Company”) announced its results of operations for the three and six months ended June 30, 2023 in a press release dated August 9, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000063/0001606498-23-000063-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}